Thank you, Tiffany, thank joining us and you for all today.
to discuss retinal through a As our progress therapy of to the detailed gene -- therapy diseases we age-related game-changing inherited to approach. by in potential diseases, Modifier homeostasis excited our well receptors modifier as the multiple in are as multifactor as nuclear macular using retina. release, address press agnostic platform hormone diseases dry degeneration gene restore the has substantial such gene larger
of Just Phase for IND quarter the of liMeliGhT trial after OCUXXX close significance we and cleared trial submission year, clinical the the the first application. this for FDA authorization geographic later XXXX. disease, third and atrophy, of dry these and the macular in OCUXXX potential targeting clinical the now in clinical quarter in expected respectively, of OCUXXXST in depth the I/II secondary application of will the of our discuss for degeneration greater milestones provided the EMA and OCUXXX I acceptability the are market with that announced U.S.-based updates Stargardt trials, Phase the III the presentation. to age-related
This therapy cell NeoCart facility gives existing advance contingent clinical manufacturing cell support for adequate upon earlier Phase III autologous the to to completed Our is our to platform material renovations funding. the therapy capability with poised personalized Ocugen year. this
lungs X a trial inhalation Phase the via a Finally, and of into routes, different of nasal I and as Diseases, clinical soon advance National into Infectious the Allergy administration Institute comparing via NIAID sponsored will OCUXXX trial OCUXXX spray. mucosal
that ready to gene candidates cell will XXXX the bellwether III clinic be the are Phase diseases confident in X and Ocugen. for we blindness treat therapy therapy With candidate,
OCUXXX one indication. the III gene a been such with are development, marks OCUXXX progress clinical becomes clinical RP. from candidate, product strides green gene as trials to We the significant to milestone X there makes to Phase now, the in broad light it to a retinitis our share pivotal remarkable therapy III the in the trial Phase gene Until therapy with market only first as advancements modified FDA leading thrilled associated XXX has pigmentosa of to begin treat mutations
option. treatment real Now RP there haven't had patients hope is who for all a
OCUXXX Our and key across trial. Phase genetic completion promising trial demonstrated including Phase I/II of already III therapy way for potential, targets. dosing mutations These track meet for various both therapeutic medicinal diseases. safety designations and treating broad endorsements BLA inherited advanced and approvals, dosage and received regulatory medicine product paving the in enrollment Commission efficacy drug, has and and clinical and levels, orphan retinal on OCUXXX's to remain approval highlight we FDA from XXXX regenerative MAA orphan European
baseline navigation the II on which across that the at treated responders second X study of improvement for clinical XXXX, untreated gene-agnostic. in an affected in liMeliGhT of We in patients the LDNA, endpoint proportion assessment, and least mutation primary include Luminance groups, arm of [indiscernible] arms, patients with control the one dosing dependent Phase focuses eyes. lux the level the and achieving study from XXX will expect trial quarter X to by begin is subjects X in
be of changing untreated secondary an the from will well. X.XlogMAR equity group control visual will measured compared low-luminance treatment of endpoint the secondary to endpoint as score The for The baseline. be the by effectiveness
LCA, from leveraging to patients congenital Phase the half I/II Additionally, favorable Phase latter dual-track in amaurosis, to trial Leber results include expand study. plan we XXXX on the a III contingent strategy, with of
unmet markets, as of and In U.S. RP from classified retinal discuss affect nearly are are there that [indiscernible]. and Europe globally heterogeneous target and diseases total a LCA XXX,XXX people the for alone, initial LCA and an our Let X.X inherited patients. estimated a group disorders LCA million to and RP patients, moment affected RP need the underserved me by take are market combined.
By establishing groups, pertinent is ultimately, a desperate and raise find our our To with result frequently LCA aim to as better patients of for by these engaging to conditions gene strive one RP clinical These in of need a evidence the potential section affected to solution patients as we sharing our patient video therapy conferences impairment I by website. encourage vision improve preserve diseases, understand to advocacy Phase his of medical experience watch or the in homeostasis visual of to revolutionize insights and blindness. in actively trial well modified treatment. patients, and our our I/II of or you
onetime our programs. a one by with therapies over These with Stargardt distinct GA the OCUXXX secondary often orphan provide various A leverage the subretinal receptor life nuclear implicated atrophy, treatment only current receptor specifically for Moving modified and geographic and to therapy on gene, dry degeneration, RORA, disease age-related of multiple OCUXXX designed target safety the in OCUXXXST multiple gene a with our pathways to macular advantage address in the of year to to treatments dAMD, development single RAR-related aiming cause potential injection. offers a consults. dAMD, require pathogenesis of accompanied per and injections
the therapy million X affects comprehensive provide about OCUXXX a XX people U.S. combined, in Our X about in and and onetime million affects potential to solution, the is XXXX, GA life. AMD began the Europe Considerable while OCUXXX. for to durable people a Dry approach million U.S. low clinical of with ArMaDa we the trial progress Phase the for been I/II Europe, doses. dosing and and second and In opportunity. made in a has cohort, medium first December completion significant market both with
phase. upcoming in and ongoing convene DSMB, for dosing is transitioned the the insights the a the and clinical the completion trial will successful later which Phase this OCUXXX. escalation Board, dose is the Safety initial Monitoring of XXXX. data Data this this in of into third we're in evaluate will the A proceeding study. third clinical with cohort update, the cohort, into II phase cohort, the trial, month to safety anticipated Following After of efficacy quarter of provide event This key expansion high-dose
dose open control safety is groups drugs OCUXXX X to a a II compared multicenter arm while expand and is X:X:X our randomized, and X controlled Phase label group. efficacy randomized study untreated in patients across dosage focusing of to on ratio ranging, I with understanding Phase and aiming
of have square. the combined. This enrolling Phase FDA from U.S. approximately therapy I/II ABCAX-associated for We be the must atrophy chart XX a older, and is candidate corrected gene treatment to XX.X total gene the designation Stargardt best disease Stargardt have also visual modified turn the XX letters millimeter using GARDian ETDRS the geographic RORA XXX,XXX EU received disease. patients. approximately more which or and or drug equity utilizes trial Participants including in Stargardt for now aged actively million people area a OCUXXXST, X.X affects between in and orphan of the retinopathies,
quarter the XXXX, approved completed XX will the Data A uses and design also and segmenting update exhibit study this Board have and escalation for XX continuation be symptoms. a low, I, the dose. clinical expect children, the month. of We into which disease subjects third Safety we I/II In adults low high dosing cohort is dose dose in trial medium dose in Phase XXXX. April involves the completed to XX trial cohorts. medium up Monitoring participants, anticipated The OCUXXXST in The to mild-to-moderate phase, X+X which Phase first
the expansion will Phase dose the II, phase, the Following trial escalation transition into phase.
varying subjects different dose X:X:X treatment efficacy This or different a into group, at for controlled expansion design phase levels, across allowing assessment randomize a use groups the untreated to dosages. will treatments, of comprehensive X
our success with their modified OCUXXX, faced for and Our OCUXXX work across OCUXXXST therapies terrible the prospect gene to of of commitment of these the losing patients benefit sight. the enduring perform
to are get medical these forward closer encouraged and trials addressing as in critical the unmet to updates by substantial look we further milestones We needs. reach and progress sharing
XX, will Corporate financial provide that, quarter first Controller, Mike? now on to to over update With I ended the our XXXX. an results March our call from turn
